Time could run out before Larry Culp can complete his turnaround plan at GE.
GE stock hasn't solved its free cash flow conundrum, and might not for some time, says a key analyst.
The stock of the maker of life sciences research technology is trading in the low teens, but a key chart indicates no price resistance until the low $20s.
David Tepper's Appaloosa LP renews calls for changes at the top.
A key chart suggests further gains in the chemical giant are possible, but be aware that it could explore lower levels of October again.
Biogen shares rose 15% Friday following upbeat results from an Alzheimer's drug test.
What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.